News

Forest Laboratories and Almirall have entered into an agreement to develop, market and distribute LAS100977 in the US. LAS100977 is an inhaled, once-daily administered long-acting beta2 agonist (LABA),

AlphaRx has signed an agreement that provides long-term supply of the active pharmaceutical ingredient (API) for ARX1088, an orally active interferon inducer intended for the adjunctive treatment of

Arno Therapeutics (Arno) has reported the dosing of the first patient in a Phase II clinical study of its third-generation camptothecin compound, AR-67, in patients with glioblastoma multiforme

Japan-based Eisai has reported completion of construction of a new manufacturing and process research center in India. Eisai Knowledge Centre is situated in the special economic zone (SEZ)

The US Patent and Trademark Office (USPTO) has allowed patent application US 11/627,863 to MDRNA. It covers methods for the delivery of a broad array of compounds with

Synta Pharmaceuticals (Synta) has initiated a Phase 2 clinical study of STA-9090 in non-small cell lung cancer (NSCLC). STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor with a

Clinuvel has announced that its photoprotective drug Afamelanotide has been granted an orphan drug designation (ODD) by the FDA for the management of solar urticaria (SU). This is

Virtual Radiologic has completed the deployment of vRad PACS, its proprietary picture communications and archiving system for radiologic case processing. Replacing previously used commercial software, vRad PACS is

Roche has licensed its P2X31 receptor program aimed at developing treatments for chronic pain to Afferent Pharmaceuticals (Afferent). In conjunction with the announcement, Afferent has successfully closed a